Medication Information Leaflet

What is this medication for?

Ixekizumab is a biologic medication which works by blocking the activity of a protein called interleukin (IL) 17A.

IL-17A levels are increased in diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis. This medication helps to reduce the activity of the immune system and the symptoms of the diseases.

Ixekizumab does not work immediately and it may take several weeks before you notice any improvement in symptoms.

How should I take/use this medication?

Ixekizumab should be used as prescribed and you should not stop using the medication without discussing it with your doctor. Stopping Ixekizumab suddenly may cause the symptoms of your condition to return.

It may be taken alone, with methotrexate, or with other disease modifying anti-rheumatic drugs (DMARDs).

Ixekizumab is available in a solution for injection that comes in a pre-filled form (ready-to-use). It is given via injection under the skin (subcutaneously) of your stomach, thigh or upper outer arm. You and your doctor will decide if you should administer Ixekizumab yourself. You or your carer should receive training on how to inject the medication from your doctor, pharmacist or specialty nurse before attempting the administration on your own. Always remember to rotate the injection site with each injection.

Your doctor will decide how much Ixekizumab you need and for how long it has to be taken.

What should I do if I forget to take/use this medication?

If you miss a dose, inject it as soon as you remember. Talk to your doctor to discuss when the next dose should be given.

What precautions should I take?

Inform your healthcare professional if:

  • You are allergic to this medication or any of the other ingredients of this medication.

  • You are pregnant, planning to become pregnant, or breastfeeding.

    • Avoid getting pregnant while you are using Ixekizumab as the effect in pregnant women is unknown. You must use effective contraception while using Ixekizumab and for at least 9 weeks after the last dose.

    • If you are breastfeeding or planning to breastfeed, discuss with your doctor to decide if you should breastfeed or use Ixekizumab. After using Ixekizumab, you should not breastfeed for at least 9 weeks after the last dose.

  • You have a history of:

    • Inflammatory bowel disease

    • Hepatitis B or Hepatitis C

    • Tuberculosis

  • You have infections or low blood counts.

  • You are planning to receive any vaccines and to avoid any live vaccinations.

What are some common side-effects of this medication?

Side effects may occur when taking Ixekizumab, but the vast majority of these tend to resolve by themselves. Common side effects include:

  • Injection site reactions like swelling, itching or bruising, which usually subside in 3 to 5 days

  • Sore throat

  • Blocked/runny nose

  • Diarrhoea

  • Cold sores

  • White patches in the mouth or on back of throat

Inform your doctor if any side effects persist, if you are unable to tolerate them or the side effects become serious.

Ixekizumab may reduce your body’s ability to fight against infections. You should consult a doctor immediately if you develop a fever or feel unwell. Inform the doctor whom you consult that you are taking Ixekizumab as the medication may need to be stopped while you are having an infection.

You may need to have regular blood tests to monitor your blood counts while on Ixekizumab.

What are some rare but serious side-effects that I need to seek medical advice immediately?

The symptoms of a drug allergy include one or more of the following:

  • Swollen face/eyes/lips/tongue

  • Difficulty in breathing

  • Itchy skin rashes over your whole body

Other rare but serious side effects include:

  • Signs of infections: fever, chills, cough, painful or bloody urination, feeling very tired or weak.

  • Signs of new onset or worsening inflammatory bowel disease: persistent or severe stomach pain or diarrhoea

If you experience any of these symptoms, you should stop your medication and see your healthcare professional immediately.

What food or medication should I avoid when I take this medication?

Please inform your doctor or pharmacist if you are taking other medications as they may interact with Ixekizumab. These include:

  • Over-the-counter medications

  • Nutritional supplements

  • Traditional or herbal remedies

Pneumococcal, influenza (flu) and Hepatitis B vaccinations are safe and may be given if required. Avoid live vaccines such as MMR (measles, mumps and rubella), OPV (oral polio vaccine), yellow fever or BCG (tuberculosis). Discuss with your doctor before receiving any vaccines.

How should I store this medication?

Ixekizumab solution for injection is a clear liquid. Its colour may vary from colourless to slightly yellow. Do not use it if the solution contains visible particles or becomes cloudy or distinctively brown.

Do not shake the pen.

Store in a refrigerator at 2-8°C. Do not freeze.

Keep in original packaging or in a black ziplock bag to protect it from light.

Keep out of the reach of children.

How should I throw away this medication safely?

You may throw this injection away along with the used needles into a metal tin or thick plastic container (eg. detergent bottles). You can also buy a container specially designed to throw sharp items, known as a sharps box, to prevent any injuries due to the needles.


If you take more than the recommended dose, please seek medical advice immediately. The information provided on this page does not replace information from your healthcare professional. Please consult your healthcare professional for more information.

This article is jointly developed by members of the National Medication Information workgroup. The workgroup consists of cluster partners (National Healthcare Group, National University Health System and SingHealth), community pharmacies (Guardian, Unity and Watsons) and Pharmaceutical Society of Singapore. The content does not reflect drug availability and supply information in pharmacies and healthcare institutions. You are advised to check with the respective institutions for such information.

Last updated on Oct 2022

Back to Top